Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul M Coplan

Showing results (1-10 of 53) with videos related to

Pageof 6
Sort By:
Postgraduate Medicine|July 7, 2018
Incidence of nonmedical use of OxyContin and other prescription opioid pain relievers before and after the introduction of OxyContin with abuse deterrent propertiesHui G Cheng, Paul M Coplan
Current Opinion in HIV and AIDS|April 18, 2009
Mathematical models and health economic aspects of microbicidesDavid P Wilson, Paul M Coplan
Science (New York, N.Y.)|June 26, 2004
Public health. Regulatory challenges in microbicide developmentPaul M Coplan, Mark Mitchnick, Zeda F Rosenberg
Journal of Comparative Effectiveness Research|August 23, 2018
Conditional power for assessing population interventionsAlexander M Walker, Paul M Coplan, Daniel C Beachler
Drug and Alcohol Dependence|July 4, 2016
Decreased diversion by doctor-shopping for a reformulated extended release oxycodone product (OxyContin)Howard D Chilcoat, Paul M Coplan, Venkatesh Harikrishnan, et al.
Postgraduate Medicine|December 16, 2016
Disproportionality analysis of buprenorphine transdermal system and cardiac arrhythmia using FDA and WHO postmarketing reporting system dataNelson E Sessler, Ekaterina Walker, Harsha Chickballapur, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 9, 2008
The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemicsDavid P Wilson, Paul M Coplan, Mark A Wainberg, et al.
Pharmacoepidemiology and Drug Safety|October 15, 2013
Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristicsPaul M Coplan, Hrishikesh Kale, Lauren Sandstrom, et al.
Postgraduate Medicine|December 7, 2016
Comparison of abuse, suspected suicidal intent, and fatalities related to the 7-day buprenorphine transdermal patch versus other opioid analgesics in the National Poison Data SystemPaul M Coplan, Nelson E Sessler, Venkatesh Harikrishnan, et al.
Therapeutic Innovation & Regulatory Science|November 23, 2025
Regulatory Challenges and Opportunities: A Review of U.S. Food and Drug Administration-Approved Artificial Intelligence and Machine Learning-Enabled Cardiovascular DevicesMahima Saini, Grishma Kc, Adrian J Williams, et al.
Pageof 6

Showing results (1-10 of 53) with videos related to

Sort By:
Pageof 6
Postgraduate Medicine|July 7, 2018
Incidence of nonmedical use of OxyContin and other prescription opioid pain relievers before and after the introduction of OxyContin with abuse deterrent propertiesHui G Cheng, Paul M Coplan
Current Opinion in HIV and AIDS|April 18, 2009
Mathematical models and health economic aspects of microbicidesDavid P Wilson, Paul M Coplan
Science (New York, N.Y.)|June 26, 2004
Public health. Regulatory challenges in microbicide developmentPaul M Coplan, Mark Mitchnick, Zeda F Rosenberg
Journal of Comparative Effectiveness Research|August 23, 2018
Conditional power for assessing population interventionsAlexander M Walker, Paul M Coplan, Daniel C Beachler
Drug and Alcohol Dependence|July 4, 2016
Decreased diversion by doctor-shopping for a reformulated extended release oxycodone product (OxyContin)Howard D Chilcoat, Paul M Coplan, Venkatesh Harikrishnan, et al.
Postgraduate Medicine|December 16, 2016
Disproportionality analysis of buprenorphine transdermal system and cardiac arrhythmia using FDA and WHO postmarketing reporting system dataNelson E Sessler, Ekaterina Walker, Harsha Chickballapur, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 9, 2008
The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemicsDavid P Wilson, Paul M Coplan, Mark A Wainberg, et al.
Pharmacoepidemiology and Drug Safety|October 15, 2013
Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristicsPaul M Coplan, Hrishikesh Kale, Lauren Sandstrom, et al.
Postgraduate Medicine|December 7, 2016
Comparison of abuse, suspected suicidal intent, and fatalities related to the 7-day buprenorphine transdermal patch versus other opioid analgesics in the National Poison Data SystemPaul M Coplan, Nelson E Sessler, Venkatesh Harikrishnan, et al.
Therapeutic Innovation & Regulatory Science|November 23, 2025
Regulatory Challenges and Opportunities: A Review of U.S. Food and Drug Administration-Approved Artificial Intelligence and Machine Learning-Enabled Cardiovascular DevicesMahima Saini, Grishma Kc, Adrian J Williams, et al.
Pageof 6